The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing...
Read moreLatest News
Category: News
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing...
Read moreTelix has submitted a marketing authorisation application (MAA) in Europe for...
Read moreTelix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing...
Read moreTelix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry...
Read moreTelix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with...
Read moreTelix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging...
Read moreTelix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May...
Read moreTelix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal...
Read moreTelix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe,...
Read moreTelix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer...
Read more